116 related articles for article (PubMed ID: 18031277)
1. Stabilization of the active form(s) of human paraoxonase by human phosphate-binding protein.
Rochu D; Chabrière E; Renault F; Elias M; Cléry-Barraud C; Masson P
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1616-20. PubMed ID: 18031277
[TBL] [Abstract][Full Text] [Related]
2. Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning.
Rochu D; Chabrière E; Masson P
Toxicology; 2007 Apr; 233(1-3):47-59. PubMed ID: 17007987
[TBL] [Abstract][Full Text] [Related]
3. Stability of highly purified human paraoxonase (PON1): association with human phosphate binding protein (HPBP) is essential for preserving its active conformation(s).
Rochu D; Renault F; Cléry-Barraud C; Chabrière E; Masson P
Biochim Biophys Acta; 2007 Jul; 1774(7):874-83. PubMed ID: 17556053
[TBL] [Abstract][Full Text] [Related]
4. Tandem purification of two HDL-associated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatography.
Renault F; Chabrière E; Andrieu JP; Dublet B; Masson P; Rochu D
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 May; 836(1-2):15-21. PubMed ID: 16595195
[TBL] [Abstract][Full Text] [Related]
5. Integrative analytical approach by capillary electrophoresis and kinetics under high pressure optimized for deciphering intrinsic and extrinsic cofactors that modulate activity and stability of human paraoxonase (PON1).
Renault F; Carus T; Cléry-Barraud C; Elias M; Chabrière E; Masson P; Rochu D
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 May; 878(17-18):1346-55. PubMed ID: 19945920
[TBL] [Abstract][Full Text] [Related]
6. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity.
James RW; Deakin SP
Free Radic Biol Med; 2004 Dec; 37(12):1986-94. PubMed ID: 15544917
[TBL] [Abstract][Full Text] [Related]
7. Asymmetric fluorogenic organophosphates for the development of active organophosphate hydrolases with reversed stereoselectivity.
Amitai G; Adani R; Yacov G; Yishay S; Teitlboim S; Tveria L; Limanovich O; Kushnir M; Meshulam H
Toxicology; 2007 Apr; 233(1-3):187-98. PubMed ID: 17129656
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity.
Tavori H; Khatib S; Aviram M; Vaya J
Bioorg Med Chem; 2008 Aug; 16(15):7504-9. PubMed ID: 18572410
[TBL] [Abstract][Full Text] [Related]
9. Macrophage paraoxonase 1 (PON1) binding sites.
Efrat M; Aviram M
Biochem Biophys Res Commun; 2008 Nov; 376(1):105-10. PubMed ID: 18762170
[TBL] [Abstract][Full Text] [Related]
10. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities.
Rock W; Rosenblat M; Miller-Lotan R; Levy AP; Elias M; Aviram M
J Agric Food Chem; 2008 Sep; 56(18):8704-13. PubMed ID: 18759451
[TBL] [Abstract][Full Text] [Related]
11. Directed evolution of serum paraoxonase PON3 by family shuffling and ancestor/consensus mutagenesis, and its biochemical characterization.
Khersonsky O; Rosenblat M; Toker L; Yacobson S; Hugenmatter A; Silman I; Sussman JL; Aviram M; Tawfik DS
Biochemistry; 2009 Jul; 48(28):6644-54. PubMed ID: 19492856
[TBL] [Abstract][Full Text] [Related]
12. Exploring the structural and functional stabilities of different paraoxonase-1 formulations through electrophoretic mobilities and enzyme activity parameters under hydrostatic pressure.
Cléry-Barraud C; Renault F; Leva J; El Bakdouri N; Masson P; Rochu D
Biochim Biophys Acta; 2009 Apr; 1794(4):680-8. PubMed ID: 19336040
[TBL] [Abstract][Full Text] [Related]
13. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity.
Costa LG; Cole TB; Vitalone A; Furlong CE
Clin Chim Acta; 2005 Feb; 352(1-2):37-47. PubMed ID: 15653099
[TBL] [Abstract][Full Text] [Related]
14. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase.
Khersonsky O; Tawfik DS
Biochemistry; 2005 Apr; 44(16):6371-82. PubMed ID: 15835926
[TBL] [Abstract][Full Text] [Related]
15. Variation in paraoxonase-1 activity and atherosclerosis.
Soran H; Younis NN; Charlton-Menys V; Durrington P
Curr Opin Lipidol; 2009 Aug; 20(4):265-74. PubMed ID: 19550323
[TBL] [Abstract][Full Text] [Related]
16. Crossroads in the evaluation of paraoxonase 1 for protection against nerve agent and organophosphate toxicity.
Valiyaveettil M; Alamneh YA; Doctor BP; Nambiar MP
Toxicol Lett; 2012 Apr; 210(1):87-94. PubMed ID: 22301377
[TBL] [Abstract][Full Text] [Related]
17. Vitamin C attenuates hypochlorite-mediated loss of paraoxonase-1 activity from human plasma.
Kunes JP; Cordero-Koning KS; Lee LH; Lynch SM
Nutr Res; 2009 Feb; 29(2):114-22. PubMed ID: 19285602
[TBL] [Abstract][Full Text] [Related]
18. Refolded Recombinant Human Paraoxonase 1 Variant Exhibits Prophylactic Activity Against Organophosphate Poisoning.
Bajaj P; Tripathy RK; Aggarwal G; Datusalia AK; Sharma SS; Pande AH
Appl Biochem Biotechnol; 2016 Sep; 180(1):165-76. PubMed ID: 27131877
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.
Harangi M; Mirdamadi HZ; Seres I; Sztanek F; Molnár M; Kassai A; Derdák Z; Illyés L; Paragh G
Transl Res; 2009 Apr; 153(4):190-8. PubMed ID: 19304278
[TBL] [Abstract][Full Text] [Related]
20. Proteomics-based approach for identification and purification of human phosphate binding apolipoprotein from amniotic fluid.
Alam M; Mahajan M; Raziuddin M; Singh TP; Yadav S
Genet Mol Res; 2009 Aug; 8(3):929-37. PubMed ID: 19731215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
